Hjem › Lungekreft › Nebraska
Kliniske studier for Lungekreft i Nebraska
19 studier for Lungekreft søker deltakere på steder i Nebraska.
Byer i Nebraska
Offisiell studietekst (engelsk)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Nebraska Medicine-Bellevue, Bellevue
- Fred and Pamela Buffett Cancer Center - Kearney, Kearney
- CHI Health Good Samaritan, Kearney
- og 5 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT04267848Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- CHI Health Saint Francis, Grand Island
- CHI Health Good Samaritan, Kearney
- Alegent Health Immanuel Medical Center, Omaha
- og 2 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
- Cancer Partners of Nebraska, Lincoln
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. okt. 2026 · NCT04181060Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NHO Revive Research Institute, LLC, Lincoln
- NHO Support Center, Lincoln
- Cancer Partners of Nebraska, Lincoln
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07222566Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
- Cancer Partners of Nebraska, Lincoln
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07489066This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Fremont, Fremont
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Grand Island, Grand Island
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Regional, Grand Island
- og 5 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06758401A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 23. sep. 2026 · NCT07063745Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Omaha
RekruttererFase 2
Alder 18 til 95 · Alle kjønn · Oppdatert 23. sep. 2026 · NCT05061550Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Mary Lanning Healthcare (MLH) - Morrison Cancer Center (MCC), Hastings
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06712316A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- NHO Revive Research Institute, Lincoln
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06793215Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
- Nebraska Hematology-Oncology (NHO), Lincoln
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 1. sep. 2026 · NCT06712355Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 17. aug. 2026 · NCT05624996Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Nebraska Cancer Specialists, Omaha
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. jul. 2026 · NCT04198766A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
- University of Nebraska Medical Center, Omaha
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 27. jul. 2026 · NCT05242965Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Nebraska Cancer Specialist, Grand Island
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. jun. 2026 · NCT06162221Integrated Cancer Repository for Cancer Research
- Mary Lanning Healthcare, Morrison Cancer Center, Hastings
- Faith Regional Health Services, Carson Cancer Center, Norfolk
- Great Plains Regional Medical Center, North Platte
- og 3 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 19 til 110 · Alle kjønn · Oppdatert 29. jun. 2026 · NCT02012699Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- University of Nebraska Medical Center, Omaha
RekruttererFase 2
Alder 18 til 70 · Alle kjønn · Oppdatert 26. jun. 2026 · NCT04614103Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
- Nebraska Cancer Specialists, Omaha
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 14. mai 2026 · NCT06922591SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Omaha
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.